global
Variables
Utilities
CUSTOM STYLES

New FDA Approval for FoundationOne Liquid CDx Biomarker Testing

September 1, 2020

On August 26th, 2020, the Food and Drug Administration (FDA) approved the FoundationOne Liquid CDx for comprehensive liquid biopsy biomarker testing for patients with any solid tumor. The FDA based their approval on analysis from multiple clinical validation studies which showed that FoundationOne Liquid CDx is very sensitive and specific in finding mutations.This approval gives patients more options for comprehensive liquid biopsy biomarker testing that were not previously available.FDA ApprovalMeaningful Breakdown of the FDA Approval from The ASCO Post

This is some text inside of a div block.

Lung cancer questions? Contact our free HelpLine at support@go2.org or 1-800-298-2436.